{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:32:06Z","timestamp":1787063526907,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.schres.2014.07.045","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T12:16:18Z","timestamp":1408536978000},"page":"90-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis"],"prefix":"10.1016","volume":"159","author":[{"given":"Rocio","family":"P\u00e9rez-Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ortiz-Garcia de la Foz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obdulia","family":"Mart\u00ednez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Amado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Garcia-Unzueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayesa-Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Suarez-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Tabares-Seisdedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.07.045_bb0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/YIC.0b013e32832c2624","article-title":"Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study","volume":"24","author":"Alptekin","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2014.07.045_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-6-8","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0015","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0020","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2014.07.045_bb0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.schres.2013.04.014","article-title":"Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial","volume":"147","author":"Crespo-Facorro","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.07.045_bb0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80mg\/day and 160mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2014.07.045_bb0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.schres.2014.07.045_bb0040","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2014.07.045_bb0045","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2014.07.045_bb0050","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2014.07.045_bb0055","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2014.07.045_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2014.07.045_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006569.pub3","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2014.07.045_bb0075","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2014.07.045_bb0085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2014.07.045_bb0090","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.schres.2014.07.045_bb0095","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20mg\/day for the treatment of patients with acute exacerbations of schizophrenia","volume":"41","author":"McEvoy","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2014.07.045_bb0100","doi-asserted-by":"crossref","first-page":"e742","DOI":"10.4088\/JCP.10r06802","article-title":"Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of Pfizer-initiated clinical trials","volume":"73","author":"Pappadopulos","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2008.08.031","article-title":"Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment","volume":"106","author":"Pena","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.07.045_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145713001053","article-title":"Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors","volume":"17","author":"Perez-Iglesias","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2014.07.045_bb0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.07.045_bb0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0125","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.045_bb0130","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414004022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414004022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:29:16Z","timestamp":1565742556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414004022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0920996414004022"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.07.045","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}